retigabine ezogabine withdrawn
Selected indexed studies
- Targeting Kv7 Potassium Channels for Epilepsy. (CNS Drugs, 2025) [PMID:39853501]
- A Novel Compound QO-83 Alleviates Acute and Chronic Epileptic Seizures in Rodents by Modulating K(V)7 Channel Activity. (CNS Neurosci Ther, 2025) [PMID:40125810]
- New K(V)7.2/3 Channel Activators Exhibit Superior Toxicity and Metabolic Profiles to Flupirtine and Demonstrate Promising In Vivo Analgesic Effects. (ACS Chem Neurosci, 2025) [PMID:40492583]
_Worker-drafted node — pending editorial review._
Connections
retigabine ezogabine withdrawn is a side effect of
Sources
- Targeting Kv7 Potassium Channels for Epilepsy. (2025) pubmed
- A Novel Compound QO-83 Alleviates Acute and Chronic Epileptic Seizures in Rodents by Modulating K(V)7 Channel Activity. (2025) pubmed
- New K(V)7.2/3 Channel Activators Exhibit Superior Toxicity and Metabolic Profiles to Flupirtine and Demonstrate Promising In Vivo Analgesic Effects. (2025) pubmed
- Pharmacological Activation of Neuronal Voltage-Gated Kv7/KCNQ/M-Channels for Potential Therapy of Epilepsy and Pain. (2021) pubmed
- Molecular Mechanisms and Structural Basis of Retigabine Analogues in Regulating KCNQ2 Channel. (2020) pubmed
- Safety of retigabine in adults with partial-onset seizures after long-term exposure: focus on unexpected ophthalmological and dermatological events. (2020) pubmed
- Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. (2003) pubmed
- Identification of a new retigabine derivative with improved photostability for selective activation of neuronal Kv7 channels and antiseizure activity. (2024) pubmed